Related Experiment Videos
[Ototoxicity of deferoxamine]
R de España1, O Biurrun, J Lorente
1Servicio de Otorrinolaringología, Hospital Clínic/Facultad de Medicina, Barcelona.
Anales Otorrinolaringologicos Ibero-Americanos
|January 1, 1992
Summary
Deferoxamine (DFO), a chelating agent for chronic renal failure, may cause hearing loss. This study found minimal ototoxicity in 15% of patients undergoing hemodialysis, recommending regular hearing checks.
Area of Science:
- Nephrology
- Otolaryngology
- Pharmacology
Context:
- Deferoxamine (DFO) is a chelating agent used in patients with chronic renal failure.
- Ototoxicity is a known potential side effect of DFO treatment.
- Patients with chronic renal failure often require chelation therapy.
Purpose:
- To investigate the otologic effects of Deferoxamine (DFO) in patients undergoing hemodialysis.
- To assess the incidence of sensorineural hearing loss associated with DFO treatment.
- To evaluate the audiological impact of DFO in a cohort of renal failure patients.
Summary:
- A study evaluated 20 patients on hemodialysis for DFO-induced ototoxicity using comprehensive audiological tests.
- Results indicated sensorineural hearing loss of retrocochlear origin in 15% (3/20) of the patients.
- The findings suggest that while DFO's ototoxic effects are minimal, they are not entirely absent.
Impact:
- Highlights the potential for DFO to cause hearing loss, even if infrequent.
- Recommends regular audiological monitoring for renal disease patients receiving DFO.
- Informs clinical practice regarding the ototoxic risks associated with DFO therapy in nephrology patients.